BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01131676
First received: May 26, 2010
Last updated: October 14, 2014
Last verified: October 2014
  Purpose

The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: BI 10773 low dose
Drug: Placebo BI 10773 high dose
Drug: BI 10773 high dose
Drug: Placebo BI 10773 low dose
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • The primary endpoint is time to the first occurrence of any of the following adjudicated components of the primary composite endpoint: cardiovascular death (including fatal stroke and fatal myocardial infarction(MI)), non-fatal MI and non-fatal stroke. [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The composite of all events adjudicated: cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke and hospitalization for unstable angina pectoris. [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
  • To determine the incidence of new onset albuminuria [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
  • To determine the incidence of silent MI [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
  • To determine the incidence of heart failure requiring hospitalization [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
  • To determine the incidence of new onset macroalbuminuria [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
  • Composite microvascular outcome [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 7000
Study Start Date: July 2010
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI 10773 low dose
BI 10773 tablets once daily
Drug: BI 10773 low dose
BI 10773 tablets once daily
Drug: Placebo BI 10773 high dose
Placebo tablets identical to BI 10773
Experimental: BI 10773 high dose
BI 10773 tablets once daily
Drug: BI 10773 high dose
BI 10773 tablets once daily
Drug: Placebo BI 10773 low dose
Placebo tablets identical to BI 10773
Placebo Comparator: Placebo
Placebo tablets matching BI 10773
Drug: Placebo BI 10773 high dose
Placebo tablets identical to BI 10773
Drug: Placebo BI 10773 low dose
Placebo tablets identical to BI 10773

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Diagnosis of type 2 diabetes mellitus prior to informed consent
  2. Male or female patients on diet and exercise regimen who are drug naive or pre treated with any background therapy. Antidiabetic therapy has to be unchanged for 12 weeks prior to randomization.
  3. Glycosylated haemoglobin (HbA1c) of >= 7.0% and <=10% for patients on background therapy or HbA1c >= 7.0% and <= 9.0% for drug naive patients
  4. Age >= 18 years
  5. Body Mass index <= 45 at Visit 1
  6. Signed and dated informed consent
  7. High cardiovascular risk

Exclusion criteria:

  1. Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day)
  2. Indication of liver disease, defined by serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase ALT or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at screening and/or run in.
  3. Planned cardiac surgery or angioplasty within 3 months
  4. Impaired renal function, defined as Glomerular Filtration Rate <30 ml/min (severe renal impairment, Modification of Diet in Renal Disease formula) during screening or run in.
  5. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption
  6. Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia)
  7. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years
  8. Contraindications to background therapy according to the local label
  9. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight
  10. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except type 2 diabetes mellitus
  11. Pre-menopausal women (last menstruation <+ 1 year prior to informed consent) who:

    • are nursing or pregnant or
    • are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems, oral, implantable or injectable contraceptives, sexual abstinence, double barrier method and vasectomised partner
  12. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake
  13. Participation in another trial with an investigational drug within 30 days prior to informed consent
  14. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial
  15. Acute coronary syndrome, stroke or TIA within 2 months prior to informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01131676

  Hide Study Locations
Locations
United States, Alabama
1245.25.10043 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1245.25.10121 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1245.25.10037 Boehringer Ingelheim Investigational Site
Huntsville, Alabama, United States
1245.25.10124 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
United States, Alaska
1245.25.10015 Boehringer Ingelheim Investigational Site
Little Rock, Alaska, United States
United States, Arizona
1245.25.10056 Boehringer Ingelheim Investigational Site
Gilbert, Arizona, United States
1245.25.10175 Boehringer Ingelheim Investigational Site
Peoria, Arizona, United States
1245.25.10072 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
United States, Arkansas
1245.25.10048 Boehringer Ingelheim Investigational Site
Harrisburg, Arkansas, United States
United States, California
1245.25.10035 Boehringer Ingelheim Investigational Site
Anaheim, California, United States
1245.25.10103 Boehringer Ingelheim Investigational Site
Encino, California, United States
1245.25.10158 Boehringer Ingelheim Investigational Site
Fresno, California, United States
1245.25.10126 Boehringer Ingelheim Investigational Site
Harbor City, California, United States
1245.25.10058 Boehringer Ingelheim Investigational Site
Huntington Park, California, United States
1245.25.10001 Boehringer Ingelheim Investigational Site
Lancaster, California, United States
1245.25.10102 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
1245.25.10047 Boehringer Ingelheim Investigational Site
Los Gatos, California, United States
1245.25.10118 Boehringer Ingelheim Investigational Site
Palm Springs, California, United States
1245.25.10061 Boehringer Ingelheim Investigational Site
Riverside, California, United States
1245.25.10040 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1245.25.10193 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1245.25.10055 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1245.25.10027 Boehringer Ingelheim Investigational Site
Santa Rosa, California, United States
1245.25.10074 Boehringer Ingelheim Investigational Site
Stockton, California, United States
1245.25.10083 Boehringer Ingelheim Investigational Site
Valencia, California, United States
United States, Colorado
1245.25.10144 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado, United States
1245.25.10085 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
1245.25.10153 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
United States, Connecticut
1245.25.10066 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut, United States
1245.25.10038 Boehringer Ingelheim Investigational Site
Waterbury, Connecticut, United States
United States, District of Columbia
1245.25.10068 Boehringer Ingelheim Investigational Site
Washington, District of Columbia, United States
United States, Florida
1245.25.10094 Boehringer Ingelheim Investigational Site
Bradenton, Florida, United States
1245.25.10190 Boehringer Ingelheim Investigational Site
Brooksville, Florida, United States
1245.25.10209 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1245.25.10212 Boehringer Ingelheim Investigational Site
Cooper City, Florida, United States
1245.25.10200 Boehringer Ingelheim Investigational Site
Delray Beach, Florida, United States
1245.25.10202 Boehringer Ingelheim Investigational Site
Hallandale Beach, Florida, United States
1245.25.10157 Boehringer Ingelheim Investigational Site
Hialeah, Florida, United States
1245.25.10063 Boehringer Ingelheim Investigational Site
Hialeah, Florida, United States
1245.25.10062 Boehringer Ingelheim Investigational Site
Hialeah, Florida, United States
1245.25.10033 Boehringer Ingelheim Investigational Site
Hollywood, Florida, United States
1245.25.10089 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1245.25.10019 Boehringer Ingelheim Investigational Site
Longwood, Florida, United States
1245.25.10168 Boehringer Ingelheim Investigational Site
Maitland, Florida, United States
1245.25.10039 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1245.25.10184 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1245.25.10018 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1245.25.10123 Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
1245.25.10201 Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
1245.25.10042 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida, United States
1245.25.10025 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida, United States
1245.25.10147 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida, United States
1245.25.10198 Boehringer Ingelheim Investigational Site
Saint Petersburg, Florida, United States
1245.25.10203 Boehringer Ingelheim Investigational Site
Saint Petersburg, Florida, United States
1245.25.10104 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1245.25.10211 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1245.25.10178 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
United States, Georgia
1245.25.10023 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1245.25.10174 Boehringer Ingelheim Investigational Site
Columbus, Georgia, United States
1245.25.10141 Boehringer Ingelheim Investigational Site
Riverdale, Georgia, United States
1245.25.10067 Boehringer Ingelheim Investigational Site
Roswell, Georgia, United States
United States, Hawaii
1245.25.10022 Boehringer Ingelheim Investigational Site
Honolulu, Hawaii, United States
United States, Idaho
1245.25.10092 Boehringer Ingelheim Investigational Site
Boise, Idaho, United States
United States, Illinois
1245.25.10097 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
United States, Indiana
1245.25.10116 Boehringer Ingelheim Investigational Site
Evansville, Indiana, United States
1245.25.10206 Boehringer Ingelheim Investigational Site
Valparaiso, Indiana, United States
United States, Kansas
1245.25.10021 Boehringer Ingelheim Investigational Site
Wichita, Kansas, United States
United States, Kentucky
1245.25.10186 Boehringer Ingelheim Investigational Site
Lexington, Kentucky, United States
1245.25.10109 Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
1245.25.10006 Boehringer Ingelheim Investigational Site
Madisonville, Kentucky, United States
1245.25.10005 Boehringer Ingelheim Investigational Site
Paducah, Kentucky, United States
United States, Louisiana
1245.25.10020 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana, United States
United States, Maine
1245.25.10012 Boehringer Ingelheim Investigational Site
Auburn, Maine, United States
United States, Maryland
1245.25.10041 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1245.25.10134 Boehringer Ingelheim Investigational Site
Hyattsville, Maryland, United States
1245.25.10210 Boehringer Ingelheim Investigational Site
Towson, Maryland, United States
United States, Massachusetts
1245.25.10064 Boehringer Ingelheim Investigational Site
Springfield, Massachusetts, United States
1245.25.10051 Boehringer Ingelheim Investigational Site
Watertown, Massachusetts, United States
United States, Michigan
1245.25.10071 Boehringer Ingelheim Investigational Site
Dearborn, Michigan, United States
1245.25.10013 Boehringer Ingelheim Investigational Site
Flint, Michigan, United States
1245.25.10107 Boehringer Ingelheim Investigational Site
Petoskey, Michigan, United States
United States, Minnesota
1245.25.10030 Boehringer Ingelheim Investigational Site
Eagan, Minnesota, United States
1245.25.10028 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
United States, Mississippi
1245.25.10176 Boehringer Ingelheim Investigational Site
Picayune, Mississippi, United States
United States, Missouri
1245.25.10011 Boehringer Ingelheim Investigational Site
Chesterfield, Missouri, United States
1245.25.10163 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
United States, Montana
1245.25.10148 Boehringer Ingelheim Investigational Site
Great Falls, Montana, United States
1245.25.10191 Boehringer Ingelheim Investigational Site
Great Falls, Montana, United States
United States, Nebraska
1245.25.10034 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
United States, New Jersey
1245.25.10014 Boehringer Ingelheim Investigational Site
Flemington, New Jersey, United States
United States, New Mexico
1245.25.10145 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
1245.25.10180 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
United States, New York
1245.25.10131 Boehringer Ingelheim Investigational Site
Binghamton, New York, United States
1245.25.10029 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
1245.25.10142 Boehringer Ingelheim Investigational Site
Smithtown, New York, United States
1245.25.10096 Boehringer Ingelheim Investigational Site
Staten Island, New York, United States
United States, North Carolina
1245.25.10196 Boehringer Ingelheim Investigational Site
Burlington, North Carolina, United States
1245.25.10207 Boehringer Ingelheim Investigational Site
Calabash, North Carolina, United States
1245.25.10053 Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States
1245.25.10010 Boehringer Ingelheim Investigational Site
Greenville, North Carolina, United States
United States, Ohio
1245.25.10060 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1245.25.10086 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1245.25.10137 Boehringer Ingelheim Investigational Site
Dayton, Ohio, United States
1245.25.10138 Boehringer Ingelheim Investigational Site
Delaware, Ohio, United States
1245.25.10156 Boehringer Ingelheim Investigational Site
Kettering, Ohio, United States
1245.25.10091 Boehringer Ingelheim Investigational Site
Marion, Ohio, United States
1245.25.10192 Boehringer Ingelheim Investigational Site
Zanesville, Ohio, United States
United States, Oklahoma
1245.25.10114 Boehringer Ingelheim Investigational Site
Norman, Oklahoma, United States
United States, Oregon
1245.25.10082 Boehringer Ingelheim Investigational Site
Eugene, Oregon, United States
United States, Pennsylvania
1245.25.10154 Boehringer Ingelheim Investigational Site
Clairton, Pennsylvania, United States
1245.25.10173 Boehringer Ingelheim Investigational Site
Clairton, Pennsylvania, United States
1245.25.10052 Boehringer Ingelheim Investigational Site
Feasterville Trevose, Pennsylvania, United States
1245.25.10069 Boehringer Ingelheim Investigational Site
Fleetwood, Pennsylvania, United States
1245.25.10172 Boehringer Ingelheim Investigational Site
Greensburg, Pennsylvania, United States
1245.25.10050 Boehringer Ingelheim Investigational Site
Indiana, Pennsylvania, United States
1245.25.10009 Boehringer Ingelheim Investigational Site
Lansdale, Pennsylvania, United States
1245.25.10214 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
1245.25.10149 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
1245.25.10197 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
1245.25.10159 Boehringer Ingelheim Investigational Site
Scottdale, Pennsylvania, United States
1245.25.10162 Boehringer Ingelheim Investigational Site
Tipton, Pennsylvania, United States
1245.25.10146 Boehringer Ingelheim Investigational Site
Uniontown, Pennsylvania, United States
1245.25.10077 Boehringer Ingelheim Investigational Site
Yardley, Pennsylvania, United States
United States, South Carolina
1245.25.10070 Boehringer Ingelheim Investigational Site
Anderson, South Carolina, United States
1245.25.10044 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
1245.25.10002 Boehringer Ingelheim Investigational Site
Greer, South Carolina, United States
1245.25.10132 Boehringer Ingelheim Investigational Site
Hodges, South Carolina, United States
1245.25.10140 Boehringer Ingelheim Investigational Site
Mt. Pleasant, South Carolina, United States
1245.25.10127 Boehringer Ingelheim Investigational Site
Myrtle Beach, South Carolina, United States
1245.25.10065 Boehringer Ingelheim Investigational Site
Myrtle Beach, South Carolina, United States
1245.25.10170 Boehringer Ingelheim Investigational Site
North Myrtle Beach, South Carolina, United States
1245.25.10129 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina, United States
1245.25.10171 Boehringer Ingelheim Investigational Site
Union, South Carolina, United States
United States, Tennessee
1245.25.10054 Boehringer Ingelheim Investigational Site
Bristol, Tennessee, United States
1245.25.10036 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee, United States
1245.25.10057 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee, United States
1245.25.10046 Boehringer Ingelheim Investigational Site
Kingsport, Tennessee, United States
1245.25.10143 Boehringer Ingelheim Investigational Site
Memphis, Tennessee, United States
United States, Texas
1245.25.10075 Boehringer Ingelheim Investigational Site
Corpus Christi, Texas, United States
1245.25.10165 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1245.25.10026 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1245.25.10007 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1245.25.10100 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1245.25.10169 Boehringer Ingelheim Investigational Site
Fort Worth, Texas, United States
1245.25.10189 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1245.25.10125 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1245.25.10003 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1245.25.10119 Boehringer Ingelheim Investigational Site
Lubbock, Texas, United States
1245.25.10078 Boehringer Ingelheim Investigational Site
New Braunfels, Texas, United States
1245.25.10076 Boehringer Ingelheim Investigational Site
Odessa, Texas, United States
1245.25.10133 Boehringer Ingelheim Investigational Site
Pearland, Texas, United States
1245.25.10160 Boehringer Ingelheim Investigational Site
Plano, Texas, United States
1245.25.10177 Boehringer Ingelheim Investigational Site
Richardson, Texas, United States
1245.25.10049 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1245.25.10161 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
United States, Utah
1245.25.10185 Boehringer Ingelheim Investigational Site
Bountiful, Utah, United States
1245.25.10155 Boehringer Ingelheim Investigational Site
Draper, Utah, United States
1245.25.10079 Boehringer Ingelheim Investigational Site
Midvale, Utah, United States
1245.25.10080 Boehringer Ingelheim Investigational Site
Salt Lake City, Utah, United States
1245.25.10087 Boehringer Ingelheim Investigational Site
South Ogden, Utah, United States
United States, Virginia
1245.25.10218 Boehringer Ingelheim Investigational Site
Burke, Virginia, United States
1245.25.10004 Boehringer Ingelheim Investigational Site
Norfolk, Virginia, United States
1245.25.10111 Boehringer Ingelheim Investigational Site
South Chesterfield, Virginia, United States
United States, Washington
1245.25.10216 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
1245.25.10115 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
1245.25.10017 Boehringer Ingelheim Investigational Site
Tacoma, Washington, United States
1245.25.10016 Boehringer Ingelheim Investigational Site
Walla Walla, Washington, United States
United States, West Virginia
1245.25.10187 Boehringer Ingelheim Investigational Site
Charleston, West Virginia, United States
1245.25.10182 Boehringer Ingelheim Investigational Site
Morgantown, West Virginia, United States
United States, Wisconsin
1245.25.10098 Boehringer Ingelheim Investigational Site
Madison, Wisconsin, United States
Argentina
1245.25.54012 Boehringer Ingelheim Investigational Site
Buenos Aires, Argentina
1245.25.54006 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1245.25.54013 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1245.25.54001 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1245.25.54011 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1245.25.54010 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1245.25.54003 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1245.25.54002 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1245.25.54005 Boehringer Ingelheim Investigational Site
Parque Velez Sarfield, Argentina
1245.25.54008 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1245.25.54009 Boehringer Ingelheim Investigational Site
Rosario, Argentina
Australia, Queensland
1245.25.61003 Boehringer Ingelheim Investigational Site
Herston, Queensland, Australia
Australia, South Australia
1245.25.61001 Boehringer Ingelheim Investigational Site
Ashford, South Australia, Australia
1245.25.61002 Boehringer Ingelheim Investigational Site
Fullarton, South Australia, Australia
Austria
1245.25.43008 Boehringer Ingelheim Investigational Site
Feldkirch, Austria
1245.25.43006 Boehringer Ingelheim Investigational Site
Graz, Austria
1245.25.43016 Boehringer Ingelheim Investigational Site
Innsbruck, Austria
1245.25.43005 Boehringer Ingelheim Investigational Site
Salzburg, Austria
1245.25.43015 Boehringer Ingelheim Investigational Site
St. Stefan, Austria
1245.25.43009 Boehringer Ingelheim Investigational Site
Wien, Austria
1245.25.43010 Boehringer Ingelheim Investigational Site
Wien, Austria
1245.25.43001 Boehringer Ingelheim Investigational Site
Wien, Austria
1245.25.43013 Boehringer Ingelheim Investigational Site
Wien, Austria
1245.25.43007 Boehringer Ingelheim Investigational Site
Wien, Austria
Belgium
1245.25.32010 Boehringer Ingelheim Investigational Site
Bonheiden, Belgium
1245.25.32030 Boehringer Ingelheim Investigational Site
Brussel, Belgium
1245.25.32011 Boehringer Ingelheim Investigational Site
Bruxelles, Belgium
1245.25.32008 Boehringer Ingelheim Investigational Site
Bruxelles, Belgium
1245.25.32003 Boehringer Ingelheim Investigational Site
De Pinte, Belgium
1245.25.32002 Boehringer Ingelheim Investigational Site
Edegem, Belgium
1245.25.32004 Boehringer Ingelheim Investigational Site
Genk, Belgium
1245.25.32029 Boehringer Ingelheim Investigational Site
Halen, Belgium
1245.25.32009 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
1245.25.32007 Boehringer Ingelheim Investigational Site
Huy, Belgium
1245.25.32013 Boehringer Ingelheim Investigational Site
La Louvière, Belgium
1245.25.32012 Boehringer Ingelheim Investigational Site
Leuven, Belgium
1245.25.32028 Boehringer Ingelheim Investigational Site
Liège, Belgium
1245.25.32001 Boehringer Ingelheim Investigational Site
Liège, Belgium
1245.25.32005 Boehringer Ingelheim Investigational Site
Massemen-Wetteren, Belgium
1245.25.32014 Boehringer Ingelheim Investigational Site
Oostham, Belgium
Brazil
1245.25.55019 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
1245.25.55014 Boehringer Ingelheim Investigational Site
Belém, Brazil
1245.25.55007 Boehringer Ingelheim Investigational Site
Boqueirão, Brazil
1245.25.55015 Boehringer Ingelheim Investigational Site
Brasília, Brazil
1245.25.55027 Boehringer Ingelheim Investigational Site
Campinas, Brazil
1245.25.55028 Boehringer Ingelheim Investigational Site
Campinas, Brazil
1245.25.55025 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
1245.25.55026 Boehringer Ingelheim Investigational Site
Fortaleza, Brazil
1245.25.55009 Boehringer Ingelheim Investigational Site
Goiânia, Brazil
1245.25.55002 Boehringer Ingelheim Investigational Site
Higienópolis, Brazil
1245.25.55017 Boehringer Ingelheim Investigational Site
Marilia, Brazil
1245.25.55022 Boehringer Ingelheim Investigational Site
Maringá, Brazil
1245.25.55008 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1245.25.55016 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1245.25.55012 Boehringer Ingelheim Investigational Site
Ribeirão Preto, Brazil
1245.25.55013 Boehringer Ingelheim Investigational Site
São José do Rio Preto, Brazil
1245.25.55004 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1245.25.55010 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1245.25.55018 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1245.25.55023 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1245.25.55006 Boehringer Ingelheim Investigational Site
Vila Albuquerque, Brazil
1245.25.55003 Boehringer Ingelheim Investigational Site
Vila Clementino, Brazil
1245.25.55005 Boehringer Ingelheim Investigational Site
Vila Leopoldina, Brazil
1245.25.55001 Boehringer Ingelheim Investigational Site
Villa Clementino, Brazil
Canada, British Columbia
1245.25.20047 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
Canada, Manitoba
1245.25.20048 Boehringer Ingelheim Investigational Site
Winnipeg, Manitoba, Canada
Canada, Nova Scotia
1245.25.20026 Boehringer Ingelheim Investigational Site
Halifax, Nova Scotia, Canada
Canada, Ontario
1245.25.20045 Boehringer Ingelheim Investigational Site
Brampton, Ontario, Canada
1245.25.20042 Boehringer Ingelheim Investigational Site
Burlington, Ontario, Canada
1245.25.20009 Boehringer Ingelheim Investigational Site
Newmarket, Ontario, Canada
1245.25.20044 Boehringer Ingelheim Investigational Site
Niagara Falls, Ontario, Canada
1245.25.20013 Boehringer Ingelheim Investigational Site
Ottawa, Ontario, Canada
1245.25.20049 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
Canada, Quebec
1245.25.20050 Boehringer Ingelheim Investigational Site
Gatineau, Quebec, Canada
1245.25.20043 Boehringer Ingelheim Investigational Site
Longueuil, Quebec, Canada
1245.25.20046 Boehringer Ingelheim Investigational Site
Longueuil, Quebec, Canada
Canada, Saskatchewan
1245.25.20041 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
Colombia
1245.25.57010 Boehringer Ingelheim Investigational Site
Armenia, Colombia
1245.25.57004 Boehringer Ingelheim Investigational Site
Barranquilla, Colombia
1245.25.57011 Boehringer Ingelheim Investigational Site
Bogotá, Colombia
1245.25.57003 Boehringer Ingelheim Investigational Site
Bogotá, Colombia
1245.25.57001 Boehringer Ingelheim Investigational Site
Bogotá, Colombia
1245.25.57006 Boehringer Ingelheim Investigational Site
Floridablanca, Colombia
1245.25.57009 Boehringer Ingelheim Investigational Site
Medellín, Colombia
Croatia
1245.25.71005 Boehringer Ingelheim Investigational Site
Karlovac, Croatia
1245.25.71001 Boehringer Ingelheim Investigational Site
Krapinske Toplice, Croatia
1245.25.71006 Boehringer Ingelheim Investigational Site
Osijek, Croatia
1245.25.71003 Boehringer Ingelheim Investigational Site
Rijeka, Croatia
1245.25.71004 Boehringer Ingelheim Investigational Site
Zagreb, Croatia
1245.25.71002 Boehringer Ingelheim Investigational Site
Zagreb, Croatia
Czech Republic
1245.25.42020 Boehringer Ingelheim Investigational Site
Brno, Czech Republic
1245.25.42018 Boehringer Ingelheim Investigational Site
Jindrichuv Hradec, Czech Republic
1245.25.42015 Boehringer Ingelheim Investigational Site
Praha 3, Czech Republic
1245.25.42019 Boehringer Ingelheim Investigational Site
Usti nad Labem, Czech Republic
Denmark
1245.25.45006 Boehringer Ingelheim Investigational Site
Frederiksberg, Denmark
1245.25.45003 Boehringer Ingelheim Investigational Site
Gentofte, Denmark
1245.25.45007 Boehringer Ingelheim Investigational Site
Helsingør, Denmark
1245.25.45002 Boehringer Ingelheim Investigational Site
København NV, Denmark
1245.25.45004 Boehringer Ingelheim Investigational Site
Randers NØ, Denmark
1245.25.45005 Boehringer Ingelheim Investigational Site
Slagelse, Denmark
Estonia
1245.25.37005 Boehringer Ingelheim Investigational Site
Tallin, Estonia
1245.25.37002 Boehringer Ingelheim Investigational Site
Tallin, Estonia
1245.25.37003 Boehringer Ingelheim Investigational Site
Tallinn, Estonia
1245.25.37001 Boehringer Ingelheim Investigational Site
Tartu, Estonia
1245.25.37004 Boehringer Ingelheim Investigational Site
Tartu, Estonia
France
1245.25.33022 Boehringer Ingelheim Investigational Site
Amiens, France
1245.25.33034 Boehringer Ingelheim Investigational Site
Angers, France
1245.25.33033 Boehringer Ingelheim Investigational Site
Angers, France
1245.25.33030 Boehringer Ingelheim Investigational Site
Bourg des cptes, France
1245.25.33023 Boehringer Ingelheim Investigational Site
Corbeil Essonnes, France
1245.25.33024 Boehringer Ingelheim Investigational Site
Derval, France
1245.25.33029 Boehringer Ingelheim Investigational Site
Equeurdreville Haineville, France
1245.25.33027 Boehringer Ingelheim Investigational Site
Fleury sur Orne, France
1245.25.33021 Boehringer Ingelheim Investigational Site
Grenoble, France
1245.25.33003 Boehringer Ingelheim Investigational Site
La Rochelle Cedex 1, France
1245.25.33032 Boehringer Ingelheim Investigational Site
Le Creusot, France
1245.25.33004 Boehringer Ingelheim Investigational Site
Narbonne Cedex, France
1245.25.33047 Boehringer Ingelheim Investigational Site
Pessac, France
1245.25.33046 Boehringer Ingelheim Investigational Site
Poitiers, France
1245.25.33025 Boehringer Ingelheim Investigational Site
Saint Priez en Jarez, France
1245.25.33035 Boehringer Ingelheim Investigational Site
Tours, France
Georgia
1245.25.99001 Boehringer Ingelheim Investigational Site
Batumi, Georgia
1245.25.99003 Boehringer Ingelheim Investigational Site
Kutaisi, Georgia
1245.25.99005 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.99007 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.99002 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.99004 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.99008 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.99006 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
Greece
1245.25.30002 Boehringer Ingelheim Investigational Site
Athens, Greece
1245.25.30004 Boehringer Ingelheim Investigational Site
Athens, Greece
1245.25.30003 Boehringer Ingelheim Investigational Site
Athens, Greece
1245.25.30007 Boehringer Ingelheim Investigational Site
Athens, Greece
1245.25.30005 Boehringer Ingelheim Investigational Site
Larissa, Greece
1245.25.30001 Boehringer Ingelheim Investigational Site
Nikaia, Greece
1245.25.30006 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
1245.25.30008 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
Hong Kong
1245.25.85207 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
1245.25.85208 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
1245.25.85201 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
1245.25.85205 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
Hungary
1245.25.36002 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1245.25.36008 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1245.25.36004 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1245.25.36006 Boehringer Ingelheim Investigational Site
Dunaujvaros, Hungary
1245.25.36001 Boehringer Ingelheim Investigational Site
Gyula, Hungary
1245.25.36010 Boehringer Ingelheim Investigational Site
Kisvarda, Hungary
1245.25.36003 Boehringer Ingelheim Investigational Site
Szekszard, Hungary
1245.25.36011 Boehringer Ingelheim Investigational Site
Szikszo, Hungary
India
1245.25.91307 Boehringer Ingelheim Investigational Site
Ahmedabad, India
1245.25.91317 Boehringer Ingelheim Investigational Site
Bangalore, India
1245.25.91320 Boehringer Ingelheim Investigational Site
Bangalore, India
1245.25.91319 Boehringer Ingelheim Investigational Site
Bangalore, India
1245.25.91302 Boehringer Ingelheim Investigational Site
Bangalore, India
1245.25.91303 Boehringer Ingelheim Investigational Site
Chennai, India
1245.25.91315 Boehringer Ingelheim Investigational Site
Cochin, India
1245.25.91311 Boehringer Ingelheim Investigational Site
Hyderabad, India
1245.25.91318 Boehringer Ingelheim Investigational Site
Indore, India
1245.25.91305 Boehringer Ingelheim Investigational Site
Jaipur, India
1245.25.91309 Boehringer Ingelheim Investigational Site
Jalandhar, India
1245.25.91324 Boehringer Ingelheim Investigational Site
Nagpur, India
1245.25.91313 Boehringer Ingelheim Investigational Site
Nagpur, India
1245.25.91301 Boehringer Ingelheim Investigational Site
Nashik, Maharashtra, India
1245.25.91308 Boehringer Ingelheim Investigational Site
Pune, India
1245.25.91316 Boehringer Ingelheim Investigational Site
Secunderabad, India
1245.25.91321 Boehringer Ingelheim Investigational Site
Varanasi, India
1245.25.91314 Boehringer Ingelheim Investigational Site
Vijaywada, India
Indonesia
1245.25.62006 Boehringer Ingelheim Investigational Site
Denpasar, Bali, Indonesia
1245.25.62009 Boehringer Ingelheim Investigational Site
Depok, Indonesia
1245.25.62002 Boehringer Ingelheim Investigational Site
Jakarta, Indonesia
1245.25.62008 Boehringer Ingelheim Investigational Site
Jakarta, Indonesia
1245.25.62010 Boehringer Ingelheim Investigational Site
Jakarta, Indonesia
1245.25.62004 Boehringer Ingelheim Investigational Site
Malang, Indonesia
1245.25.62003 Boehringer Ingelheim Investigational Site
Surabaya, Indonesia
1245.25.62001 Boehringer Ingelheim Investigational Site
Yogyakarta, Indonesia
Israel
1245.25.97003 Boehringer Ingelheim Investigational Site
Afula, Israel
1245.25.97006 Boehringer Ingelheim Investigational Site
Hadera, Israel
1245.25.97008 Boehringer Ingelheim Investigational Site
Haifa, Israel
1245.25.97009 Boehringer Ingelheim Investigational Site
Holon, Israel
1245.25.97005 Boehringer Ingelheim Investigational Site
Nahariya, Israel
1245.25.97001 Boehringer Ingelheim Investigational Site
Safed, Israel
1245.25.97002 Boehringer Ingelheim Investigational Site
Zerifin, Israel
Italy
1245.25.39007 Boehringer Ingelheim Investigational Site
Bologna, Italy
1245.25.39002 Boehringer Ingelheim Investigational Site
Campobasso, Italy
1245.25.39008 Boehringer Ingelheim Investigational Site
Catanzaro, Italy
1245.25.39010 Boehringer Ingelheim Investigational Site
Chieti, Italy
1245.25.39024 Boehringer Ingelheim Investigational Site
Ferrara, Italy
1245.25.39009 Boehringer Ingelheim Investigational Site
Firenze, Italy
1245.25.39005 Boehringer Ingelheim Investigational Site
Foggia, Italy
1245.25.39004 Boehringer Ingelheim Investigational Site
Napoli, Italy
1245.25.39006 Boehringer Ingelheim Investigational Site
Padova, Italy
1245.25.39001 Boehringer Ingelheim Investigational Site
Pisa, Italy
1245.25.39003 Boehringer Ingelheim Investigational Site
Roma, Italy
1245.25.39011 Boehringer Ingelheim Investigational Site
Roma, Italy
1245.25.39012 Boehringer Ingelheim Investigational Site
Roma, Italy
1245.25.39014 Boehringer Ingelheim Investigational Site
Roma, Italy
1245.25.39013 Boehringer Ingelheim Investigational Site
Venezia, Italy
Japan
1245.25.81008 Boehringer Ingelheim Investigational Site
Chuo-ku, tokyo, Japan
1245.25.81010 Boehringer Ingelheim Investigational Site
Gifushi, Gifu, Japan
1245.25.81002 Boehringer Ingelheim Investigational Site
Hanyushi, Saitama, Japan
1245.25.81013 Boehringer Ingelheim Investigational Site
Kamigyo-ku, Kyotoshi, Kyoto, Japan
1245.25.81003 Boehringer Ingelheim Investigational Site
Kishiwadashi. Osaka, Japan
1245.25.81012 Boehringer Ingelheim Investigational Site
Kita-ku, Nagoyashi, Aichi, Japan
1245.25.81014 Boehringer Ingelheim Investigational Site
Kumamoto-shi, Kumamoto, Japan
1245.25.81001 Boehringer Ingelheim Investigational Site
Matsudoshi, Chiba, Japan
1245.25.81006 Boehringer Ingelheim Investigational Site
Mitoshi, Ibaraki, Japan
1245.25.81005 Boehringer Ingelheim Investigational Site
Nishi-ku, Sapporoshi, Hokkaido, Japan
1245.25.81007 Boehringer Ingelheim Investigational Site
Nodashi, Chiba, Japan
1245.25.81004 Boehringer Ingelheim Investigational Site
Shimajiri-gun,Okinawa, Japan
1245.25.81009 Boehringer Ingelheim Investigational Site
Toyamashi, Toyama, Japan
1245.25.81015 Boehringer Ingelheim Investigational Site
Toyoakeshi, Aichi, Japan
Korea, Republic of
1245.25.82030 Boehringer Ingelheim Investigational Site
Busan, Korea, Republic of
1245.25.82018 Boehringer Ingelheim Investigational Site
Daegu, Korea, Republic of
1245.25.82021 Boehringer Ingelheim Investigational Site
Daejeon, Korea, Republic of
1245.25.82031 Boehringer Ingelheim Investigational Site
Daejoen, Korea, Republic of
1245.25.82027 Boehringer Ingelheim Investigational Site
Goyang, Korea, Republic of
1245.25.82022 Boehringer Ingelheim Investigational Site
Gwangju, Korea, Republic of
1245.25.82029 Boehringer Ingelheim Investigational Site
Incheon, Korea, Republic of
1245.25.82017 Boehringer Ingelheim Investigational Site
Pusan, Korea, Republic of
1245.25.82020 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1245.25.82023 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1245.25.82015 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1245.25.82025 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1245.25.82024 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1245.25.82016 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1245.25.82019 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1245.25.82026 Boehringer Ingelheim Investigational Site
Suwon, Korea, Republic of
1245.25.82028 Boehringer Ingelheim Investigational Site
Wonju, Korea, Republic of
Malaysia
1245.25.60019 Boehringer Ingelheim Investigational Site
Johor Bahru, Malaysia
1245.25.60020 Boehringer Ingelheim Investigational Site
Kedah, Malaysia
1245.25.60013 Boehringer Ingelheim Investigational Site
Kelantan, Malaysia
1245.25.60015 Boehringer Ingelheim Investigational Site
Kota Kinabalu, Malaysia
1245.25.60017 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
1245.25.60012 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
1245.25.60004 Boehringer Ingelheim Investigational Site
Pahang, Malaysia
1245.25.60016 Boehringer Ingelheim Investigational Site
Selangor, Malaysia
1245.25.60021 Boehringer Ingelheim Investigational Site
Selangor, Malaysia
1245.25.60018 Boehringer Ingelheim Investigational Site
Selangor Darul Ehsan, Malaysia
Mexico
1245.25.52009 Boehringer Ingelheim Investigational Site
Colonia Americana, Mexico
1245.25.52007 Boehringer Ingelheim Investigational Site
Distrito Federal, Mexico
1245.25.52013 Boehringer Ingelheim Investigational Site
Ladron de Guevara, Mexico
1245.25.52010 Boehringer Ingelheim Investigational Site
Los Robles, Mexico
1245.25.52001 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
1245.25.52011 Boehringer Ingelheim Investigational Site
Reforma Social, Mexico
1245.25.52012 Boehringer Ingelheim Investigational Site
San Lucas tepetlcalco, Mexico
Netherlands
1245.25.31015 Boehringer Ingelheim Investigational Site
Amersfoort, Netherlands
1245.25.31013 Boehringer Ingelheim Investigational Site
Apeldoorn, Netherlands
1245.25.31036 Boehringer Ingelheim Investigational Site
Baarle - Nassau, Netherlands
1245.25.31032 Boehringer Ingelheim Investigational Site
Delft, Netherlands
1245.25.31026 Boehringer Ingelheim Investigational Site
Den Helder, Netherlands
1245.25.31012 Boehringer Ingelheim Investigational Site
Geleen, Netherlands
1245.25.31017 Boehringer Ingelheim Investigational Site
Hardenberg, Netherlands
1245.25.31035 Boehringer Ingelheim Investigational Site
Heerlen, Netherlands
1245.25.31011 Boehringer Ingelheim Investigational Site
Hoogeveen, Netherlands
1245.25.31029 Boehringer Ingelheim Investigational Site
Hoogezand, Netherlands
1245.25.31023 Boehringer Ingelheim Investigational Site
Hoogwoud, Netherlands
1245.25.31009 Boehringer Ingelheim Investigational Site
Maastricht, Netherlands
1245.25.31031 Boehringer Ingelheim Investigational Site
Meppel, Netherlands
1245.25.31024 Boehringer Ingelheim Investigational Site
Nijverdal, Netherlands
1245.25.31033 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
1245.25.31014 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
1245.25.31030 Boehringer Ingelheim Investigational Site
Schiedam, Netherlands
1245.25.31002 Boehringer Ingelheim Investigational Site
Utrecht, Netherlands
1245.25.31028 Boehringer Ingelheim Investigational Site
Wildervank, Netherlands
1245.25.31034 Boehringer Ingelheim Investigational Site
Zutphen, Netherlands
New Zealand
1245.25.64004 Boehringer Ingelheim Investigational Site
Christchurch, New Zealand
1245.25.64001 Boehringer Ingelheim Investigational Site
Grafton / Auckland, New Zealand
1245.25.64003 Boehringer Ingelheim Investigational Site
Wellington, New Zealand
Norway
1245.25.47002 Boehringer Ingelheim Investigational Site
Fornebu, Norway
1245.25.47004 Boehringer Ingelheim Investigational Site
Gjøvik, Norway
1245.25.47009 Boehringer Ingelheim Investigational Site
Kløfta, Norway
1245.25.47008 Boehringer Ingelheim Investigational Site
Kongsvinger, Norway
1245.25.47006 Boehringer Ingelheim Investigational Site
Oslo, Norway
1245.25.47001 Boehringer Ingelheim Investigational Site
Oslo, Norway
1245.25.47007 Boehringer Ingelheim Investigational Site
Trondheim, Norway
1245.25.47005 Boehringer Ingelheim Investigational Site
Tynset, Norway
Peru
1245.25.51008 Boehringer Ingelheim Investigational Site
Arequipa, Peru
1245.25.51001 Boehringer Ingelheim Investigational Site
Arequipa, Peru
1245.25.51002 Boehringer Ingelheim Investigational Site
Bellavista, Peru
1245.25.51004 Boehringer Ingelheim Investigational Site
El Agustino, Peru
1245.25.51006 Boehringer Ingelheim Investigational Site
Ica, Peru
1245.25.51003 Boehringer Ingelheim Investigational Site
Jesus Maria, Peru
1245.25.51009 Boehringer Ingelheim Investigational Site
Lima, Peru
1245.25.51010 Boehringer Ingelheim Investigational Site
Lima, Peru
1245.25.51011 Boehringer Ingelheim Investigational Site
Lima, Peru
1245.25.51007 Boehringer Ingelheim Investigational Site
Lima, Peru
1245.25.51005 Boehringer Ingelheim Investigational Site
Miraflores, Peru
Philippines
1245.25.63016 Boehringer Ingelheim Investigational Site
Cavite City, Philippines
1245.25.63002 Boehringer Ingelheim Investigational Site
Cebu, Philippines
1245.25.63003 Boehringer Ingelheim Investigational Site
Davao, Philippines
1245.25.63020 Boehringer Ingelheim Investigational Site
Jaro Iloilo City, Philippines
1245.25.63018 Boehringer Ingelheim Investigational Site
Manila, Philippines
1245.25.63004 Boehringer Ingelheim Investigational Site
Manila, Philippines
1245.25.63001 Boehringer Ingelheim Investigational Site
Manila, Philippines
1245.25.63009 Boehringer Ingelheim Investigational Site
Marikina City, Philippines
1245.25.63021 Boehringer Ingelheim Investigational Site
Marikina City, Philippines
1245.25.63019 Boehringer Ingelheim Investigational Site
Tarlac, Philippines
Poland
1245.25.48013 Boehringer Ingelheim Investigational Site
Gdansk, Poland
1245.25.48010 Boehringer Ingelheim Investigational Site
Lodz, Poland
1245.25.48009 Boehringer Ingelheim Investigational Site
Lodz, Poland
1245.25.48004 Boehringer Ingelheim Investigational Site
Lodz, Poland
1245.25.48001 Boehringer Ingelheim Investigational Site
Lublin, Poland
1245.25.48014 Boehringer Ingelheim Investigational Site
Oswiecim, Poland
1245.25.48002 Boehringer Ingelheim Investigational Site
Poznan, Poland
1245.25.48008 Boehringer Ingelheim Investigational Site
Pulawy, Poland
1245.25.48007 Boehringer Ingelheim Investigational Site
Ruda Slaska, Poland
1245.25.48011 Boehringer Ingelheim Investigational Site
Torun, Poland
1245.25.48005 Boehringer Ingelheim Investigational Site
Torun, Poland
Portugal
1245.25.35006 Boehringer Ingelheim Investigational Site
Amadora, Portugal
1245.25.35004 Boehringer Ingelheim Investigational Site
Coimbra, Portugal
1245.25.35018 Boehringer Ingelheim Investigational Site
Faro, Portugal
1245.25.35021 Boehringer Ingelheim Investigational Site
Funchal, Portugal
1245.25.35008 Boehringer Ingelheim Investigational Site
Leiria, Portugal
1245.25.35002 Boehringer Ingelheim Investigational Site
Lisboa, Portugal
1245.25.35015 Boehringer Ingelheim Investigational Site
Lisboa, Portugal
1245.25.35017 Boehringer Ingelheim Investigational Site
Lisboa, Portugal
1245.25.35001 Boehringer Ingelheim Investigational Site
Lisboa, Portugal
1245.25.35011 Boehringer Ingelheim Investigational Site
Porto, Portugal
1245.25.35005 Boehringer Ingelheim Investigational Site
Santiago do Cacém, Portugal
1245.25.35020 Boehringer Ingelheim Investigational Site
Torres Novas, Portugal
1245.25.35014 Boehringer Ingelheim Investigational Site
Viana do Castelo, Portugal
1245.25.35019 Boehringer Ingelheim Investigational Site
Vila Nova de Gaia, Portugal
Romania
1245.25.40008 Boehringer Ingelheim Investigational Site
Alba Iulia, Romania
1245.25.40011 Boehringer Ingelheim Investigational Site
Baia Mare Maramures, Romania
1245.25.40003 Boehringer Ingelheim Investigational Site
Bucharest, Romania
1245.25.40007 Boehringer Ingelheim Investigational Site
Bucharest, Romania
1245.25.40005 Boehringer Ingelheim Investigational Site
Constanta, Romania
1245.25.40006 Boehringer Ingelheim Investigational Site
Craiova, Romania
1245.25.40002 Boehringer Ingelheim Investigational Site
Craiova, Romania
1245.25.40009 Boehringer Ingelheim Investigational Site
Oradea, Romania
1245.25.40010 Boehringer Ingelheim Investigational Site
Targu-Mures, Romania
Russian Federation
1245.25.70019 Boehringer Ingelheim Investigational Site
Barnaul, Russian Federation
1245.25.70015 Boehringer Ingelheim Investigational Site
Kemerovo, Russian Federation
1245.25.70020 Boehringer Ingelheim Investigational Site
Kemerovo, Russian Federation
1245.25.70016 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1245.25.70011 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1245.25.70009 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1245.25.70003 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1245.25.70022 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1245.25.70021 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1245.25.70024 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
1245.25.70014 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
1245.25.70028 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
1245.25.70018 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
1245.25.70027 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russian Federation
1245.25.70025 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russian Federation
1245.25.70026 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russian Federation
1245.25.70005 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russian Federation
1245.25.70013 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1245.25.70001 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1245.25.70023 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1245.25.70004 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1245.25.70017 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1245.25.70006 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1245.25.70002 Boehringer Ingelheim Investigational Site
Vsevolozhsk, Russian Federation
1245.25.70029 Boehringer Ingelheim Investigational Site
Yaroslavl, Russian Federation
Singapore
1245.25.65001 Boehringer Ingelheim Investigational Site
Singapore, Singapore
1245.25.65003 Boehringer Ingelheim Investigational Site
Singapore, Singapore
1245.25.65004 Boehringer Ingelheim Investigational Site
Singapore, Singapore
South Africa
1245.25.76007 Boehringer Ingelheim Investigational Site
Alberton, South Africa
1245.25.76002 Boehringer Ingelheim Investigational Site
Bellville, South Africa
1245.25.76014 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1245.25.76020 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1245.25.76022 Boehringer Ingelheim Investigational Site
Chatsworth Unit 10, South Africa
1245.25.76016 Boehringer Ingelheim Investigational Site
Durban, South Africa
1245.25.76013 Boehringer Ingelheim Investigational Site
Durban, South Africa
1245.25.76019 Boehringer Ingelheim Investigational Site
Durban, South Africa
1245.25.76003 Boehringer Ingelheim Investigational Site
Goodwood, South Africa
1245.25.76001 Boehringer Ingelheim Investigational Site
Houghton, South Africa
1245.25.76021 Boehringer Ingelheim Investigational Site
Kempton Park, South Africa
1245.25.76017 Boehringer Ingelheim Investigational Site
Krugersdorp, South Africa
1245.25.76004 Boehringer Ingelheim Investigational Site
Newtown, South Africa
1245.25.76006 Boehringer Ingelheim Investigational Site
Paarl, South Africa
1245.25.76005 Boehringer Ingelheim Investigational Site
Parow, South Africa
1245.25.76018 Boehringer Ingelheim Investigational Site
Port Elizabeth, South Africa
1245.25.76015 Boehringer Ingelheim Investigational Site
Somerset West, South Africa
1245.25.76012 Boehringer Ingelheim Investigational Site
Sydenham, South Africa
1245.25.76008 Boehringer Ingelheim Investigational Site
Tongaat, South Africa
1245.25.76023 Boehringer Ingelheim Investigational Site
Worcester, South Africa
Spain
1245.25.34025 Boehringer Ingelheim Investigational Site
Alcorcon (Madrid), Spain
1245.25.34048 Boehringer Ingelheim Investigational Site
Alicante, Spain
1245.25.34050 Boehringer Ingelheim Investigational Site
Alzira, Spain
1245.25.34039 Boehringer Ingelheim Investigational Site
Avila, Spain
1245.25.34040 Boehringer Ingelheim Investigational Site
Badía del Vallès - Barcelona, Spain
1245.25.34029 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1245.25.34049 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1245.25.34030 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1245.25.34031 Boehringer Ingelheim Investigational Site
Granada, Spain
1245.25.34024 Boehringer Ingelheim Investigational Site
Leganes (Madrid), Spain
1245.25.34023 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34013 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34038 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34033 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34036 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34026 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34028 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34022 Boehringer Ingelheim Investigational Site
Mahadahonda (Madrid), Spain
1245.25.34047 Boehringer Ingelheim Investigational Site
Palma de Mallorca, Spain
1245.25.34034 Boehringer Ingelheim Investigational Site
Sabadell (Barcelona), Spain
1245.25.34027 Boehringer Ingelheim Investigational Site
Salamanca, Spain
1245.25.34037 Boehringer Ingelheim Investigational Site
Santa Cruz de Tenerife, Spain
1245.25.34046 Boehringer Ingelheim Investigational Site
Segovia, Spain
Sri Lanka
1245.25.94002 Boehringer Ingelheim Investigational Site
Colombo, Sri Lanka
1245.25.94005 Boehringer Ingelheim Investigational Site
Kalubowila, Sri Lanka
1245.25.94006 Boehringer Ingelheim Investigational Site
Kandy, Sri Lanka
1245.25.94004 Boehringer Ingelheim Investigational Site
Kandy, Sri Lanka
1245.25.94001 Boehringer Ingelheim Investigational Site
Nugegoda, Sri Lanka
1245.25.94003 Boehringer Ingelheim Investigational Site
Ragama, Sri Lanka
Taiwan
1245.25.88022 Boehringer Ingelheim Investigational Site
Hualien, Taiwan
1245.25.88010 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
1245.25.88019 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
1245.25.88020 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1245.25.88009 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1245.25.88018 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
1245.25.88016 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1245.25.88015 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1245.25.88023 Boehringer Ingelheim Investigational Site
Tamsui, Taipei county, Taiwan
1245.25.88017 Boehringer Ingelheim Investigational Site
Taoyuan, Taiwan
Thailand
1245.25.66006 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
1245.25.66007 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
1245.25.66009 Boehringer Ingelheim Investigational Site
Chiang Mai, Thailand
1245.25.66004 Boehringer Ingelheim Investigational Site
Muang District, Thailand
1245.25.66010 Boehringer Ingelheim Investigational Site
Nakhonratchasima, Thailand
1245.25.66011 Boehringer Ingelheim Investigational Site
Pathum Tani, Thailand
Ukraine
1245.25.75011 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1245.25.75009 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1245.25.75001 Boehringer Ingelheim Investigational Site
Kharkov, Ukraine
1245.25.75008 Boehringer Ingelheim Investigational Site
Kharkov, Ukraine
1245.25.75012 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
1245.25.75007 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
1245.25.75010 Boehringer Ingelheim Investigational Site
Odessa, Ukraine
United Kingdom
1245.25.44045 Boehringer Ingelheim Investigational Site
Airdrie, United Kingdom
1245.25.44020 Boehringer Ingelheim Investigational Site
Ashford, United Kingdom
1245.25.44013 Boehringer Ingelheim Investigational Site
Blackpool, United Kingdom
1245.25.44014 Boehringer Ingelheim Investigational Site
Bolton, United Kingdom
1245.25.44021 Boehringer Ingelheim Investigational Site
Bradford on Avon, United Kingdom
1245.25.44002 Boehringer Ingelheim Investigational Site
Dumfries, United Kingdom
1245.25.44009 Boehringer Ingelheim Investigational Site
Dundee, United Kingdom
1245.25.44005 Boehringer Ingelheim Investigational Site
Edinburgh, United Kingdom
1245.25.44004 Boehringer Ingelheim Investigational Site
Fowey, United Kingdom
1245.25.44001 Boehringer Ingelheim Investigational Site
Frome, United Kingdom
1245.25.44003 Boehringer Ingelheim Investigational Site
Inverness, United Kingdom
1245.25.44044 Boehringer Ingelheim Investigational Site
Wishaw, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Eli Lilly and Company
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided by Boehringer Ingelheim

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01131676     History of Changes
Other Study ID Numbers: 1245.25, 2009-016178-33
Study First Received: May 26, 2010
Last Updated: October 14, 2014
Health Authority: Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica
Australia: Responsible Ethics Committee
Austria: Medicines and Medical Devices Agency
Belgium: Federal Agency for Medicinal and Health Products
Brazil: National Health Surveillance Agency
Canada: Health Canada
Colombia: Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Croatia: Agency for Medicinal Product and Medical Devices
Czech Republic: State Institute for Drug Control
Denmark: The Danish Health and Medicines Authority
Estonia: The State Agency of Medicine
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Georgia: Ministry of Health
Greece: Ethics Committee
Hong Kong: Department of Health
Hungary: National Institute of Pharmacy
India: Drugs Controller General of India
Indonesia: National Agency of Drug and Food Control
Israel: Israeli Health Ministry Pharmaceutical Administration
Italy: Ethics Committee
Japan: Ministry of Health, Labor and Welfare
Malaysia: Ministry of Health
Mexico: Federal Commission for Protection Against Health Risks
Netherlands: Central Committee Research Involving Human Subjects
New Zealand: Medsafe
Norway: Norwegian Medicines Agency
Peru: General Directorate of Pharmaceuticals, Devices, and Drugs
Philippines: Bureau of Food and Drugs
Poland: Registration Medicinal Product Medical Device Biocidal Product
Portugal: National Pharmacy and Medicines Institute
Romania: National Medicines Agency
Russia: Pharmacological Committee, Ministry of Health
Singapore: Health Sciences Authority
South Africa: Medicines Control Council
South Korea: Ministry of Food and Drug Safety (MFDS)
Spain: Spanish Agency of Medicines
Sri Lanka: Ministry of Healthcare and Nutrition
Taiwan : Food and Drug Administration
Thailand: Food and Drug Administration
Ukraine: State Pharmacological Center - Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on October 21, 2014